London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Efficacy and safety of collagen matrix implants in trabeculectomy: comparison with 5-Fluorouracil augmented trabeculectomy

Poster Details

First Author: W.Shihadeh JORDAN

Co Author(s):                  

Abstract Details


To assess the safety and efficacy of collagen matrix implants (OlogenTM ) in trabeculectomy and to compare the results with 5-Fluorouracil (5-FU) augmented trabeculectomy.


Department of Ophthalmology/King Abdullah University Hospital/ Jordan University of Science & Technology


We compared eleven eyes of ten patients treated with Ologen-assisted trabeculectomy (Group 1) with nineteen eyes of nineteen patients treated with 5-FU augmented trabeculectomy (Group 2). All patients had moderate to advanced glaucoma with uncontrolled intraocular pressure (IOP) on maximally tolerated medical treatment. Fornix-based trabeculectomy was performed in all patients by the same surgeon.


 The two groups were comparable in age and sex distribution  Mean follow up was 12 months (range: 6-18) in Group 1 and 14 months (3-36) in Group 2.  With successful IOP control defined as corrected IOP ≤ 21 mmHg with at least 20% reduction from baseline on the same or fewer number of pre-trabeculectomy medications, 9 out of 11 eyes (81.8%) fit the criteria for success over the course of follow up (p ‹ 0.05) in Group 1 while 16 out of 19 eyes (84.2%) fit the same criteria in Group 2.  Complications: Two eyes in Group1 and three eyes in Group 2 required further procedures to lower IOP. No significant complications were encountered


The use of OlogenTM matrix implants in trabeculectomy appears to be safe and has comparable success rates to the use of 5FU FINANCIAL INTEREST: NONE

Back to Poster listing